Novo Nordisk shareholders elect new board at extraordinary general meeting

Novo Nordisk shareholders elected a new board of directors at an extraordinary general meeting on Nov. 14, 2025, installing Lars Rebien Sørensen as chair ^[1][2]. Coverage of the vote described the company's largest owner, the Novo Nordisk Foundation, as taking control of the board ^[2].

The meeting began at 2 p.m. Central European Time on Friday, Nov. 14, 2025 ^[1]. The stated purpose was to elect new members of the board of directors of Novo Nordisk A/S, and the company listed no other agenda item ^[1]. The board now consists of Sørensen as chair, Cees de Jong as vice chair, Britt Meelby Jensen, Kasim Kutay and Stephan Engels, plus four employee-elected members ^[2]. Shareholders approved the slate put forward by the Foundation ^[2].

General meetings at Novo Nordisk are called with three to five weeks' notice ^[1]. Shareholders could vote by proxy or by correspondence through the company's investor portal, and they could submit questions ahead of the meeting; Novo Nordisk posted the questions it received from shareholders on Nov. 13, 2025, the day before the meeting ^[1]. Shareholders registered for the meeting could also ask questions in writing during the session through the Computershare meeting services application ^[1]. The meeting was held in English with simultaneous interpretation into Danish, and the company said shareholders could submit questions in Danish if they preferred ^[1].

Novo Nordisk published minutes and voting results from the meeting as a document ^[1]. Individual vote totals for each director candidate were not given on the meeting page ^[1].

Why it matters for patients

Novo Nordisk is the manufacturer of the semaglutide medicines Ozempic, Wegovy and Rybelsus. A board election does not change which medicines are approved, what they are labeled to treat, or whether an insurer pays for them. Those decisions rest with the Food and Drug Administration and with pharmacy benefit plans, not with a drugmaker's board. A board's influence runs to company strategy: who serves as chief executive, how much is invested in manufacturing capacity, how products are priced, and which research programs are prioritized.

None of that has been spelled out in this vote. The information available describes who sits on the board and the fact that shareholders approved the slate ^[1][2]. It does not describe the new board's plans for supply, pricing or research, and no statement of intent appeared in the meeting materials ^[1]. Whether the change leads to any shift in the availability or cost of semaglutide medicines has not been reported.

For people taking these drugs, prescriptions, prior authorizations and refills are handled by clinicians, insurers and pharmacies. A change in board membership at the manufacturer does not, by itself, alter any of those steps. It may take months before any strategic effect, if there is one, becomes visible in company decisions.

What happens next

Novo Nordisk keeps a financial calendar and publishes an annual report covering its financial, social and environmental performance ^[1]. The meeting page does not list a date for the 2026 annual general meeting, and no timetable for further board changes has been disclosed ^[1]. The minutes and voting results document posted after the Nov. 14 meeting contains the formal record of the election ^[1].

Where the company goes next on GLP-1 manufacturing, pricing or pipeline decisions has not yet been announced.